Bristol Myers Squibb's stock is up more than 17% so far this year. The company could be acquired by

Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radio

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably alrea

Here is how Bristol Myers Squibb (BMY) and Caris Life Sciences,?Inc. (CAI) have performed compared t

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

AbbVie continues to diversify its revenue streams with successful expansions in immunology and aesth

[url="]Bristol Myers Squibb[/url] (NYSE: BMY) will announce results for the third quarter of 2026 on

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Third Quarter 2026 on O

Bristol Myers Squibb (BMY) closed the most recent trading day at $62.84, moving 1.19% from the previ

Bristol Myers Squibb (BMY) 2-year Phase 3 data shows Sotyktu maintains durable efficacy and safety i

These data are being presented at the Congress of Clinical Rheumatology - West (CCR-West) in Hunting

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CCRWest2026--Bristol Myers Squibb Presents Sotyktu Data S

Piper Sandler analyst David Amsellem reiterates Bristol-Myers Squibb (NYSE:BMY) with a Overweight

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.

Eyepoint Pharmaceuticals (NASDAQ: EYPT - Get Free Report) and Bristol Myers Squibb (NYSE: BMY - Get

Patent cliff concerns continue to weigh down Bristol Myers Squibb's stock. The pharmaceutical compan

The exercise is simple: how large a position in Bristol Myers Squibb (NYSE:BMY | BMY Price Predictio

Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.

Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its

HSBC analyst Rajesh Kumar maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the pr

Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthe

Don't catch a falling knife.

Bristol Myers Squibb reported positive Phase 2 results for its arlo-cel therapy, meeting key endpoin

Collecting $1,000 a month in dividends sounds simple until you realize the capital required shifts e

Social Security's projected 2027 COLA raise sounds promising until you realize retirees feel higher

Trial met primary endpoint of overall response rate and key secondary endpoint of complete response

Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effect

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Bristol Myers Squibb (NYSE:BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE

Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector.

Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therap

Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has

In the complaint, the Company requests, among other things: a judgment declaring that the Company do

Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more

China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s

During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst rati

New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Nex

FDA grants Replimune accelerated approval for TUDRIQEV in combination with nivolumab to treat advanc

Argus Research analyst Jasper Hellweg upgrades Bristol-Myers Squibb (NYSE:BMY) from Hold to Buy a

Citigroup analyst Geoff Meacham maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and rais

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation

Crude tumbles nearly 6% after Trump cancels a strike on Iran, lifting the S&P 500 1.3% and the R

Falling Oil Please click here for an enlarged chart of United States Oil ETF (NYSE:USO). N

Bristol Myers Squibb and AstraZeneca in talks for a $400B mega-merger, potentially creating the worl

Jim Cramer senses a 'fake out' in the rumored $400B AstraZeneca and Bristol Myers Squibb meg

U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lo

Atkore Inc (ATKR) shares rise on strong Q3 results and acquisition by Prysmian for $95.00 per share.